Position	Date of Offer	Declined or Accepted	Date of Receipt (if applicable)	Details of Gift/Hospitality Sponsorship	Estimated Value	Supplier/Offeror (or provider / giver's) Name and Nature of Business	Reason for Accepting or Declining
Senior Pharmaceutical Advisor		Accepted		Educational professional day conference, Hospitality - lunch, refreshments, coach shuttle to and from station.	£130.00		Seen as a valuable learning event for the organisation, amongst the presence of other ICBs pharmacy staff and NHS England representatives. PrescQipp is an independent, not for profit social enterprise and which support quality prescribing in the NHS. Their work is unbiased and aligned to our medicines optimisation agenda.
Director Corporate services	25/11/2022	Declined	N/A	Box of chocolates	£20.00	Rainbow Services, 2 Wych Elm, Harlow, Essex	Declined as per HWE ICB Standards of Business Conduct policy
CHC Team office manager at Place - West Essex	Dec-22	Declined	Dec-22	Gift Hamper	Unknown		Declined as per HWE ICB Standards of Business Conduct policy
Chief Executive Officer		Accepted	16/02/2023	One lunch (food only)	£25.00-£30.00	KPMG	To provide an opportunity to catch up informally with a previous colleague

	1.		I-			1 7
Primary Care	Accepted	Daichii Sankyo	Free training session (1 hour, online via Teams)	£0	Daichii Sankyo	
Clinical		UK 6th October	•Daichii Sankyo UK: Atrial Fibrillation Disease		UK	
Pharmacist		2022	Awareness and Edoxaban Overview		AstraZeneca	
Tutor		AstraZeneca 3rd	oPotential drugs discussed incl.		Eli Lilly	
		November 2022	warfarin/edoxaban (Lixiana)/apixaban			
		Eli Lilly 19th	(Eliquis)/rivaroxaban (Xarelto)/dabigatran			
		January 2023	(Pradaxa)			
			 AstraZeneca: Unmet Needs in Asthma 			
			oPotential drugs discussed incl.			
			salbutamol/inhaled corticosteroids/LABAs			
			(possible brands mentioned incl.			
			Fostair/Symbicort)			
			•Eli Lilly: Oral therapies for patients with type 2			
			diabetes			
			oPotential drugs discussed incl.			
			metformin/gliclazide/thiazolidinediones/DPP-4			
			inhibitors			
			(alogliptin/linagliptin/vildagliptin/saxagliptin/sitaglip			
			tin)/SGLT2 inhibitors			
			(empaglifozin/canaglifozin/dapaglifozin/ertuglifozi			
			n)/oral GLP-1 Ras/insulin			
					4	
L						